Related references
Note: Only part of the references are listed.Comparison between epidermal growth factor receptor (EGFR) gene expression in primary non-small cell lung cancer (NSCLC) and in fine-needle aspirates from distant metastatic sites
Cecilia Bozzetti et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Tissue heterogeneity of EGFR mutation in lung adenocarcinoma
Akira Sakurada et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
A. G. Pallis et al.
BRITISH JOURNAL OF CANCER (2007)
Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: Correlation with clinical outcome
Anastassios V. Koutsopoulos et al.
LUNG CANCER (2007)
A multiscale computational approach to dissect early events in the erb family receptor mediated activation, differential signaling, and relevance to oncogenic transformations
Yingting Liu et al.
ANNALS OF BIOMEDICAL ENGINEERING (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Lung cancer cell lines harboring MET gene amplification are dependent on met for growth and survival
Bart Lutterbach et al.
CANCER RESEARCH (2007)
Activation state egfr and STAT-3 as prognostic markers in resected non-small cell lung cancer
Tania Cortas et al.
LUNG CANCER (2007)
EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer
N. van Zandwijk et al.
ANNALS OF ONCOLOGY (2007)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer
Fred R. Hirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Frequent EGFR mutations in brain metastases of lung adenocarcinoma
Shingo Matsumoto et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer
Meng-Heng Hsieh et al.
LUNG CANCER (2006)
The role of companion diagnostics in the development and use of mutation-targeted cancer therapies
Nickolas Papadopoulos et al.
NATURE BIOTECHNOLOGY (2006)
Significance of EGFR protein expression and gene amplification in non-small cell luna carcinoma
Sanja Dacic et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2006)
Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors
A Italiano et al.
ANNALS OF ONCOLOGY (2006)
Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer
Rafal Dziadziuszko et al.
CLINICAL CANCER RESEARCH (2006)
Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation
SW Han et al.
CLINICAL CANCER RESEARCH (2006)
High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH
C Garnis et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer
Anne S. Tsao et al.
JOURNAL OF THORACIC ONCOLOGY (2006)
Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants
YR Chen et al.
ONCOGENE (2006)
High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor
N Fujimoto et al.
CANCER RESEARCH (2005)
Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer
T Takano et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study
FR Hirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas
M Taron et al.
CLINICAL CANCER RESEARCH (2005)
Erlotinib in lung cancer - Molecular and clinical predictors of outcome
MS Tsao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer
TY Chou et al.
CLINICAL CANCER RESEARCH (2005)
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
W Pao et al.
PLOS MEDICINE (2005)
Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa (R), ZD1839) in chemotherapy-resistant non-small cell lung cancer
SW Han et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Molecular footprints of human lung cancer progression
J Yokota et al.
CANCER SCIENCE (2004)
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways
R Sordella et al.
SCIENCE (2004)
Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer
R Pérez-Soler et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Loss of heterozygosity of chromosome 3p21 is associated with mutant TP53 and better patient survival in non-small-cell lung
CJ Marsit et al.
CANCER RESEARCH (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Metastatic potential: Generic predisposition of the primary tumor or rare, metastatic variants - or both?
RO Hynes
CELL (2003)
Gene expression profiling predicts clinical outcome of breast cancer
LJ van't Veer et al.
NATURE (2002)
Share Paper
